Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

PSTV

Plus Therapeutics Inc

May 22 • 04:00PM ET

2.18

Dollar change +0.05
Percentage change 2.35	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-3.19	Insider Own	2.58%	Shs Outstand	5.70M	Perf Week	-6.03%
Market Cap	12.43M	Forward P/E	-	EPS next Y	-2.79	Insider Trans	45.83%	Shs Float	5.56M	Perf Month	33.74%
Income	-11.77M	PEG	-	EPS next Q	-0.64	Inst Own	1.77%	Short Float	0.83%	Perf Quarter	12.95%
Sales	6.08M	P/S	2.04	EPS this Y	41.98%	Inst Trans	-4.92%	Short Ratio	0.63	Perf Half Y	14.74%
Book/sh	-1.13	P/B	-	EPS next Y	-13.55%	ROA	-110.75%	Short Interest	0.05M	Perf Year	-44.25%
Cash/sh	0.56	P/C	3.86	EPS next 5Y	-	ROE	-522.50%	52W Range	0.97 - 4.45	Perf YTD	24.56%
Dividend Est.	-	P/FCF	-	EPS past 5Y	68.20%	ROI	-	52W High	-51.01%	Beta	0.57
Dividend TTM	-	Quick Ratio	0.41	Sales past 5Y	406.45%	Gross Margin	87.77%	52W Low	124.88%	ATR (14)	0.16
Dividend Ex-Date	-	Current Ratio	0.41	EPS Y/Y TTM	71.07%	Oper. Margin	-195.59%	RSI (14)	60.09	Volatility	6.14% 8.68%
Employees	20	Debt/Eq	-	Sales Y/Y TTM	733.42%	Profit Margin	-193.49%	Recom	1.00	Target Price	19.33
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	63.56%	Payout	-	Rel Volume	0.12	Prev Close	2.13
Sales Surprise	-1.35%	EPS Surprise	31.19%	Sales Q/Q	231.42%	Earnings	May 15 AMC	Avg Volume	73.73K	Price	2.18
SMA20	9.18%	SMA50	16.00%	SMA200	17.71%	Trades		Volume	8,629	Change	2.35%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-25-21	Initiated	Ladenburg Thalmann	Buy	$8
Oct-16-20	Initiated	Maxim Group	Buy	$6

May-17-24 05:00PM	Plus Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
May-16-24 03:05AM	Plus Therapeutics Inc (PSTV) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ... (GuruFocus.com)
May-15-24 08:53PM	PSTV Stock Earnings: Plus Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) +6.91%
04:15PM	Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
May-13-24 07:30AM	Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024 (GlobeNewswire)
11:29AM	Loading…
May-09-24 11:29AM	Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial (GlobeNewswire)
May-08-24 05:35PM	Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial (GlobeNewswire) +6.57%
May-06-24 07:30AM	Plus Therapeutics Announces Private Placement Financing of up to $18 Million (GlobeNewswire) +11.67%
Apr-22-24 09:00AM	Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense (Benzinga)
07:00AM	Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense (GlobeNewswire)
Apr-09-24 07:00AM	Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus' Management Team (GlobeNewswire)
Mar-27-24 08:00AM	Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference (GlobeNewswire)
Mar-25-24 08:00AM	Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic (GlobeNewswire)
Mar-11-24 07:00AM	Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases (GlobeNewswire)
Mar-07-24 08:59AM	Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript (Insider Monkey) -10.59%
01:43PM	Loading…
Mar-06-24 01:43PM	Q4 2023 Plus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -11.24%
Mar-05-24 09:52PM	PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
05:35PM	Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire)
Feb-27-24 08:00AM	Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024 (GlobeNewswire) +6.01%
Dec-18-23 07:00AM	Plus Updates Financial and Cash Guidance for 2024 (GlobeNewswire)
Dec-12-23 08:00AM	Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses (GlobeNewswire)
Nov-29-23 08:00AM	Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe (GlobeNewswire) -5.56%
Nov-20-23 07:00AM	Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar (GlobeNewswire) -27.76%
Nov-15-23 07:00AM	Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023 (GlobeNewswire) +12.43%
Nov-13-23 09:31AM	Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals? (PR Newswire)
Nov-03-23 07:00AM	Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases (GlobeNewswire) +17.65%
Nov-01-23 09:29AM	Plus Therapeutics, Inc. (NASDAQ:PSTV) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.74%
Oct-31-23 04:10PM	Plus Therapeutics Announces Share Repurchase Program (GlobeNewswire) +10.92%
04:05PM	Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
09:21AM	Loading…
Oct-25-23 09:21AM	Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar (GlobeNewswire) -7.34%
Oct-23-23 04:05PM	Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023 (GlobeNewswire) -5.22%
Oct-10-23 07:00AM	Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium ( Re) Obisbemeda in Leptomeningeal Metastases (GlobeNewswire) +5.04%
Oct-09-23 07:00AM	Plus Therapeutics to Participate in the Jones Trading Healthcare Summit and ThinkEquity Conference in October (GlobeNewswire)
Sep-19-23 01:07PM	Targeted Cancer Treatment: Plus Therapeutics CEO Marc Hedrick, Live from NYSE (Exec Edge)
Sep-15-23 11:17AM	Director Howard Clowes Buys 6,993 Shares of Plus Therapeutics Inc (GuruFocus.com)
Sep-11-23 12:44PM	Plus Therapeutics Presents Cancer Treatment Data at Conference (Exec Edge) +8.70%
07:00AM	Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference (GlobeNewswire)
Sep-08-23 12:49PM	Plus Therapeutics Expands Biocept Partnership with Diagnostic Platform (Exec Edge) -53.54%
11:18AM	Why Is Cancer Diagnostic Focused Biocept Stock Trading Higher Today? (Benzinga)
08:30AM	EXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System Cancers (Benzinga)
07:00AM	Plus Therapeutics Enters into License Agreement for Cerebrospinal Fluid Tumor Cell Enumeration Assay (GlobeNewswire)
Sep-05-23 01:13PM	Plus Therapeutics Trialing Cancer Treatment for Cerebrospinal Fluid (Exec Edge)
07:00AM	Plus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase (GlobeNewswire)
Aug-30-23 07:00AM	Plus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-18-23 09:55AM	Plus (PSTV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-15-23 10:58AM	Q2 2023 Plus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 04:05PM	Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Aug-11-23 06:28PM	Positive Results Unveiled for Targeted CNS Cancer Treatment in Recent Study by Plus Therapeutics (Exec Edge) -20.89%
08:00AM	EXCLUSIVE: Plus Therapeutics Lead Candidate Shows Preliminary Safety, Efficacy In Type Of Brain Cancer (Benzinga)
06:30AM	Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at the 2023 SNO/ASCO CNS Cancer Conference (GlobeNewswire)
Aug-08-23 04:05PM	Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023 (GlobeNewswire)
11:22AM	Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conference (GlobeNewswire)
Aug-03-23 07:00AM	Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-27-23 05:34PM	Plus Therapeutics Appoints Dr. Pius Maliakal as VP of Clinical Operations (Exec Edge) -9.02%
04:05PM	Plus Therapeutics Strengthens Clinical Program with the Appointment of Pius Maliakal as Vice President of Clinical Operations (GlobeNewswire)
07:00AM	Plus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer Conference (GlobeNewswire)
Jul-13-23 07:00AM	Plus Therapeutics to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit (GlobeNewswire)
Jun-29-23 07:00AM	Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT Clinical Trials at SNMMI Annual Meeting (GlobeNewswire) -5.38%
Jun-14-23 07:00AM	Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (GlobeNewswire) -10.68%
Jun-08-23 07:00AM	Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting (GlobeNewswire)
Jun-01-23 07:00AM	Plus Therapeutics Provides Company Update Today (GlobeNewswire)
May-30-23 07:00AM	Plus Therapeutics Announces Topline Results from Recurrent Glioblastoma External Control Analysis at ASCO 2023 (GlobeNewswire) -7.19%
May-25-23 07:00AM	Plus Therapeutics to Present at the 2023 Virtual June Investor Summit (GlobeNewswire)
May-16-23 07:00AM	Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire) -7.09%
May-12-23 07:00AM	Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event (GlobeNewswire) -8.47%
May-02-23 07:00AM	Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials (GlobeNewswire) -7.27%
Apr-28-23 12:55PM	Plus Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Apr-21-23 09:01AM	Q1 2023 Plus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -13.98%
Apr-20-23 05:25PM	Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.83%
04:05PM	Plus Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Apr-19-23 07:00AM	Plus Therapeutics Completes Enrollment of the Original Three Patients Required for Cohort 8 of ReSPECT-GBM Phase 1/2a Trial (GlobeNewswire)
Apr-18-23 04:15PM	Plus Therapeutics to Participate in Panel at the Canaccord Genuity Horizons in Oncology Virtual Conference (GlobeNewswire)
07:00AM	Plus Therapeutics Completes Phase 1/Part A of the ReSPECT-LM Clinical Trial for Leptomeningeal Metastases (GlobeNewswire)
Apr-12-23 07:00AM	Plus Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on April 20, 2023 (GlobeNewswire)
Mar-28-23 07:00AM	Plus Therapeutics Successfully Treats First Patient in Cohort 8 of ReSPECT-GBM Phase 1/2a Trial (GlobeNewswire)
Mar-22-23 07:00AM	Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal Metastases (GlobeNewswire)
Feb-23-23 05:35PM	Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Feb-14-23 07:00AM	Plus Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023 (GlobeNewswire)
Feb-01-23 07:00AM	Plus Therapeutics Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (¹Re) Obisbemeda for the Treatment of Leptomeningeal Metastases (GlobeNewswire) -8.29%
Jan-18-23 07:00AM	Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma (GlobeNewswire)
Jan-05-23 04:15PM	Plus Therapeutics: Targeting Brain Cancer with Rifle-Shot Precision (IPO-Edge.com)
Nov-21-22 06:53AM	Plus Therapeutics Highlights Updates On Lead Program In Brain Cancer Indications (Benzinga)
Nov-19-22 08:24AM	Plus Therapeutics Provides Updates on ReSPECT Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (GlobeNewswire)
Nov-02-22 07:00AM	Plus Therapeutics to Provide Update on ReSPECT Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (GlobeNewswire) -6.38%
Oct-26-22 07:00AM	Plus Therapeutics Announces Selection of Rhenium (186Re) Obisbemeda as International Non-Proprietary Name for 186RNL (GlobeNewswire)
Oct-20-22 04:05PM	Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Oct-19-22 07:00AM	Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress (GlobeNewswire)
Oct-18-22 07:00AM	Plus Therapeutics to Present at the ThinkEquity Conference (GlobeNewswire) -6.77%
Oct-06-22 07:00AM	Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022 (GlobeNewswire) +14.69%
Oct-05-22 07:00AM	Plus Therapeutics Announces Patient Webinar in Recognition of Breast Cancer Awareness Month (GlobeNewswire)
Oct-04-22 07:15AM	Plus Therapeutics to Share Data in Oral Presentations from Ongoing ReSPECT Clinical Trials at the 35th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire) +5.34%
Sep-22-22 08:35AM	Why Are Plus Therapeutics Shares Gaining Today? (Benzinga)
07:00AM	Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas (GlobeNewswire)
Sep-12-22 07:00AM	Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022 (GlobeNewswire) -11.44%
Sep-08-22 07:00AM	Plus Therapeutics to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Sep-06-22 07:00AM	Plus Therapeutics Announces FDA Meeting Summary for Lead Drug Candidate (GlobeNewswire) -12.14%
Aug-29-22 07:00AM	Plus Therapeutics Announces Summary of FDA Meeting on Companys cGMP Manufacturing Process for Lead Drug Candidate (GlobeNewswire) +14.55%
Aug-23-22 07:00AM	Plus Therapeutics to Present Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022 (GlobeNewswire) +10.16%

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Petersen Greg	Director	May 08 '24	Buy	2.04	12,255	25,000	36,421	May 10 07:30 AM
HEDRICK MARC H	Chief Executive Officer	May 08 '24	Buy	2.04	12,255	25,000	12,425	May 10 07:30 AM
Clowes Howard	Director	May 08 '24	Buy	2.04	9,804	20,000	21,497	May 10 07:30 AM
Hawkins Richard J	Director	May 08 '24	Buy	2.04	4,902	10,000	4,903	May 10 07:30 AM
Sims Andrew John Hugh MacIntyr	Chief Financial Officer	May 08 '24	Buy	2.04	4,902	10,000	5,717	May 10 07:30 AM
Lenk Robert P	Director	May 08 '24	Buy	2.04	4,167	8,501	29,327	May 10 07:30 AM
HEDRICK MARC H	Chief Executive Officer	Nov 20 '23	Sale	1.96	2,068	4,053	170	Dec 15 05:09 PM
Lenk Robert P	Director	Nov 16 '23	Buy	1.95	1,000	1,950	25,160	Nov 17 07:00 AM
Lenk Robert P	Director	Nov 15 '23	Buy	1.77	1,000	1,770	24,160	Nov 17 07:00 AM
Lenk Robert P	Director	Nov 13 '23	Buy	1.43	4,000	5,720	23,160	Nov 15 07:00 AM
Lenk Robert P	Director	Nov 10 '23	Buy	1.45	2,000	2,900	19,160	Nov 15 07:00 AM
Lenk Robert P	Director	Nov 09 '23	Buy	1.59	4,199	6,676	17,160	Nov 13 07:00 AM
Lenk Robert P	Director	Nov 08 '23	Buy	1.65	5,000	8,250	12,961	Nov 13 07:00 AM
Lenk Robert P	Director	Nov 07 '23	Buy	1.64	6,000	9,840	7,961	Nov 08 07:00 AM
Lenk Robert P	Director	Nov 06 '23	Buy	1.50	1,395	2,092	1,961	Nov 08 07:00 AM
Clowes Howard	Director	Sep 13 '23	Buy	1.43	6,993	10,022	11,693	Sep 15 07:00 AM
Petersen Greg	Director	Sep 11 '23	Buy	1.70	20,000	34,062	24,166	Sep 12 07:00 AM
Clowes Howard	Director	Jun 06 '23	Buy	3.98	1,000	3,980	4,700	Jun 08 07:00 AM

Open in Screener

LUMO

Lumos Pharma Inc

May 22 • 04:00PM ET

2.57

Dollar change +0.05
Percentage change 1.98	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF DFAC DFUS DFAT DCOR

Index	-	P/E	-	EPS (ttm)	-4.59	Insider Own	36.14%	Shs Outstand	8.10M	Perf Week	14.73%
Market Cap	20.87M	Forward P/E	-	EPS next Y	-1.81	Insider Trans	-0.09%	Shs Float	5.18M	Perf Month	-8.21%
Income	-37.13M	PEG	-	EPS next Q	-1.21	Inst Own	26.01%	Short Float	5.79%	Perf Quarter	-14.90%
Sales	1.52M	P/S	13.73	EPS this Y	23.83%	Inst Trans	7.76%	Short Ratio	9.88	Perf Half Y	-16.01%
Book/sh	2.15	P/B	1.19	EPS next Y	43.09%	ROA	-80.89%	Short Interest	0.30M	Perf Year	-30.73%
Cash/sh	2.85	P/C	0.90	EPS next 5Y	15.20%	ROE	-106.15%	52W Range	2.01 - 4.55	Perf YTD	-19.18%
Dividend Est.	-	P/FCF	-	EPS past 5Y	20.27%	ROI	-156.90%	52W High	-43.52%	Beta	0.66
Dividend TTM	-	Quick Ratio	6.24	Sales past 5Y	106.75%	Gross Margin	97.57%	52W Low	27.86%	ATR (14)	0.22
Dividend Ex-Date	-	Current Ratio	6.24	EPS Y/Y TTM	-24.35%	Oper. Margin	-2586.30%	RSI (14)	44.25	Volatility	9.53% 8.37%
Employees	33	Debt/Eq	0.37	Sales Y/Y TTM	-27.48%	Profit Margin	-2434.69%	Recom	1.00	Target Price	22.50
Option/Short	No / Yes	LT Debt/Eq	0.36	EPS Q/Q	-44.50%	Payout	-	Rel Volume	0.21	Prev Close	2.52
Sales Surprise	-45.00%	EPS Surprise	-13.56%	Sales Q/Q	-76.12%	Earnings	May 15 BMO	Avg Volume	30.36K	Price	2.57
SMA20	-8.05%	SMA50	-6.92%	SMA200	-16.37%	Trades		Volume	6,495	Change	1.98%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-21	Upgrade	Stifel	Hold → Buy	$4 → $24
Dec-03-20	Initiated	Cantor Fitzgerald	Buy	$32
Aug-26-20	Initiated	Piper Sandler	Overweight	$26
Aug-17-20	Resumed	ROTH Capital	Buy	$51
Aug-04-20	Initiated	H.C. Wainwright	Buy	$33

May-20-24 04:05PM	Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024 (GlobeNewswire)
May-16-24 03:02AM	Lumos Pharma Inc (LUMO) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial ... (GuruFocus.com) +17.41%
May-14-24 10:53PM	LUMO Stock Earnings: Lumos Pharma Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -11.30%
04:15PM	Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 02:51PM	Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024 (GlobeNewswire)
04:05PM	Loading…
Apr-18-24 04:05PM	Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings (GlobeNewswire)
Mar-20-24 08:00AM	Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042 (GlobeNewswire) +7.33%
Mar-08-24 02:06PM	Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-07-24 09:54PM	LUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023 (InvestorPlace)
04:01PM	Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update (GlobeNewswire)
Feb-26-24 09:00AM	Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024 (GlobeNewswire)
Feb-05-24 04:05PM	Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-04-24 04:05PM	Lumos Pharma Promotes Pisit Duke Pitukcheewanont, MD to Chief Medical Officer (GlobeNewswire)
Nov-21-23 04:15PM	Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency (GlobeNewswire)
Nov-20-23 04:05PM	Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November (GlobeNewswire)
04:35PM	Loading…
Nov-07-23 04:35PM	Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates (GlobeNewswire)
04:01PM	Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints (GlobeNewswire)
Sep-26-23 09:00AM	Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting (GlobeNewswire)
Sep-14-23 08:00AM	Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting (GlobeNewswire)
Sep-07-23 04:34PM	Lumos Pharma Announces Participation in Investor Conferences in September (GlobeNewswire)
Aug-22-23 09:00AM	Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape (GlobeNewswire) +7.61%
Aug-09-23 04:01PM	Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update (GlobeNewswire) -5.85%
Jul-26-23 09:00AM	Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023 (GlobeNewswire)
Jul-12-23 08:00AM	Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit (GlobeNewswire) +6.25%
Jun-28-23 04:01PM	Lumos Pharma Announces Departure of Chief Medical Officer (GlobeNewswire)
Jun-21-23 09:00AM	Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar (GlobeNewswire)
May-31-23 08:00AM	Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference (GlobeNewswire) -7.32%
May-25-23 08:00AM	Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st (GlobeNewswire)
May-22-23 09:00AM	Lumos Pharma to Participate in World Orphan Drug Congress USA (GlobeNewswire) +6.61%
May-08-23 08:00AM	Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES) (GlobeNewswire)
04:05PM	Loading…
May-03-23 04:05PM	Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates (GlobeNewswire)
Apr-27-23 09:00AM	Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES) (GlobeNewswire)
Apr-19-23 09:00AM	Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023 (GlobeNewswire) -5.83%
Mar-09-23 04:05PM	Lumos Pharma to Participate in Oppenheimers 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023 (GlobeNewswire)
Mar-05-23 02:00PM	Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology (GlobeNewswire)
Mar-01-23 04:05PM	Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates (GlobeNewswire)
Feb-28-23 04:05PM	Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD (GlobeNewswire) +5.20%
Feb-15-23 04:05PM	Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023 (GlobeNewswire)
Jan-03-23 09:00AM	Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023 (GlobeNewswire) +8.03%
Dec-12-22 07:30AM	KOL Review of Lumos Pharmas Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients (GlobeNewswire) -15.75%
Nov-29-22 04:05PM	Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD (GlobeNewswire)
Nov-22-22 04:05PM	Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) +5.85%
Nov-14-22 06:10AM	Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates (GlobeNewswire) -34.68%
06:00AM	Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency (GlobeNewswire)
Sep-26-22 04:05PM	Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference (GlobeNewswire)
Aug-31-22 09:00AM	Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-16-22 07:30AM	Lumos Pharma Announces Share Repurchase Program (GlobeNewswire)
Aug-09-22 04:01PM	Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates (GlobeNewswire) -5.26%
Jul-27-22 04:05PM	Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022 (GlobeNewswire)
Jul-24-22 08:27AM	Quite a few insiders invested in Lumos Pharma, Inc. (NASDAQ:LUMO) last year which is positive news for shareholders (Simply Wall St.)
Jul-20-22 08:32PM	Our long-term outlook for the stock market remains bullish: Here are 2 stocks that Oppenheimer likes (TipRanks)
May-16-22 04:05PM	Lumos Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-10-22 04:01PM	Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates (GlobeNewswire)
May-06-22 10:25AM	Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation (Simply Wall St.)
May-05-22 09:00AM	Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial (GlobeNewswire)
Apr-26-22 09:00AM	Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022 (GlobeNewswire) +7.50%
Apr-11-22 08:30AM	Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD (GlobeNewswire)
Mar-23-22 04:05PM	Lumos Pharma to Participate in the Cantor Rare Disease Symposium (GlobeNewswire)
Mar-10-22 04:01PM	Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials (GlobeNewswire)
09:00AM	Lumos Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-23-22 09:00AM	Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022 (GlobeNewswire)
Feb-14-22 12:05PM	Great news for Lumos Pharma, Inc. (NASDAQ:LUMO): Insiders acquired stock in large numbers last year (Simply Wall St.)
Jan-05-22 09:00AM	Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (GlobeNewswire)
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-21-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com) +6.19%
Dec-16-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-08-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com) +6.03%
Nov-24-21 10:00AM	Down 16.1% in 4 Weeks, Here's Why Lumos (LUMO) Looks Ripe for a Turnaround (Zacks)
Nov-15-21 11:14AM	We're Hopeful That Lumos Pharma (NASDAQ:LUMO) Will Use Its Cash Wisely (Simply Wall St.)
Nov-10-21 05:06PM	Lumos Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-08-21 10:42AM	Wall Street Analysts Predict a 190% Upside in Lumos (LUMO): Here's What You Should Know (Zacks)
Nov-03-21 04:01PM	Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates (GlobeNewswire)
Oct-21-21 04:05PM	Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021 (GlobeNewswire)
Sep-02-21 08:00AM	Lumos Pharma to Participate in September Investor Conferences (GlobeNewswire)
Aug-16-21 09:58AM	Great news for Lumos Pharma, Inc. (NASDAQ:LUMO): Insiders acquired stock in large numbers last year (Simply Wall St.)
Aug-05-21 08:00AM	Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates (GlobeNewswire)
Aug-03-21 08:00AM	Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer (GlobeNewswire) -9.04%
Aug-02-21 08:00AM	Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President (GlobeNewswire) +10.66%
Jul-26-21 04:18PM	Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board (GlobeNewswire)
Jul-22-21 08:00AM	Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021 (GlobeNewswire)
Jul-20-21 04:01PM	Lumos Pharma Announces Clinical Updates (GlobeNewswire)
Jun-28-21 08:00AM	Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment (GlobeNewswire)
May-19-21 09:00AM	Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-13-21 09:00AM	Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit (GlobeNewswire)
May-05-21 04:01PM	Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates (GlobeNewswire) -7.41%
02:30PM	Lumos Pharma Inc to Host Earnings Call (ACCESSWIRE)
Apr-28-21 09:00AM	Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021 (GlobeNewswire)
Apr-27-21 08:00AM	Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar (GlobeNewswire)
Apr-20-21 04:05PM	Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession (GlobeNewswire)
Apr-14-21 04:05PM	Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency (GlobeNewswire) +5.78%
Mar-20-21 11:00AM	Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency (GlobeNewswire)
Mar-11-21 04:05PM	Lumos Pharma to Participate in March 2021 Investor Conferences (GlobeNewswire)
Mar-09-21 04:05PM	Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD (GlobeNewswire)
01:30PM	Lumos Pharma Inc to Host Earnings Call (ACCESSWIRE)
Mar-04-21 09:00AM	Data Supporting Use of Predictive Enrichment Markers for Lumos Pharmas LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society (GlobeNewswire) -5.82%
Mar-02-21 04:05PM	Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD at the Endocrine Society (ENDO) 2021 Annual Meeting (GlobeNewswire)
12:30PM	Will Lumos Pharma (LUMO) Report Negative Earnings Next Week? What You Should Know (Zacks)
Feb-22-21 04:15PM	Lumos Pharma to Report Full Year 2020 Financial Results and Host Conference Call on March 9, 2021 (GlobeNewswire) -5.92%
Feb-16-21 04:01PM	Lumos Pharma Announces Changes to its Board of Directors (GlobeNewswire)
Dec-18-20 09:00AM	Lumos Pharma to Participate in the H.C. Wainwright BioConnect 2021 Conference (GlobeNewswire)

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McKew John C.	Chief Scientific Officer	Apr 03 '24	Sale	2.77	2,214	6,144	17,153	Apr 03 05:10 PM
McKew John C.	Chief Scientific Officer	Feb 06 '24	Sale	3.03	438	1,328	18,403	Feb 07 05:22 PM
McKew John C.	Chief Scientific Officer	Aug 02 '23	Sale	3.21	3,407	10,919	18,707	Aug 03 04:58 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

PSTV

Plus Therapeutics Inc

LUMO

Lumos Pharma Inc

Upgrade your FINVIZ experience